Login / Signup

Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Pierre-Louis ToutainPeggy GandiaJean-Louis MontastrucAlain Bousquet-MélouPeter LeesAude A FerranPierre-Louis Toutain
Published in: Clinical pharmacokinetics (2020)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes